The catalyst for a seller to consider a potential direct secondary are many and varied, including but not limited to:

• Focusing on recently raised funds;
• Providing liquidity to limited partners;
• Limited or no capital reserves for follow-on financing;
• Dissolution of a partnership;
• Capital reallocation;
• Loss of key personnel.

Few secondary funds have purchased direct secondaries in healthcare due to the complexity of the sector and lack of expertise and interest level in actively managing a portfolio post-transaction.

Bio Equity has deep domain expertise across all sectors of healthcare, including, but not limited to, medical devices, biotech, diagnostics, specialty pharmaceuticals, healthcare IT and services.  We understand the complexity and sensitivity in direct secondary transactions for both the healthcare investors and companies. We work closely with each seller and company to ensure a seamless transition.